Guardion Health Sciences, Inc. (GHSI)
USD 3.22
(0.0%)
USD 3.22
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.92 Million USD | -333.27% |
| 2022 | -6.07 Million USD | 117.56% |
| 2021 | -9.7 Million USD | -15.59% |
| 2020 | -8.34 Million USD | 5.05% |
| 2019 | -9.99 Million USD | -49.17% |
| 2018 | -7.46 Million USD | -13.28% |
| 2017 | -5.16 Million USD | -41.99% |
| 2016 | -4.58 Million USD | 53.24% |
| 2015 | -8.03 Million USD | -1067.7% |
| 2014 | -665.92 Thousand USD | 19.55% |
| 2013 | -827.76 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -1.36 Million USD | 2.17% |
| 2024 Q1 | -1.01 Million USD | -102.7% |
| 2023 Q3 | -1.81 Million USD | -141.7% |
| 2023 FY | - USD | -333.27% |
| 2023 Q1 | -3.35 Million USD | -149.82% |
| 2023 Q2 | -752.51 Thousand USD | 77.59% |
| 2023 Q4 | -687.3 Thousand USD | 62.21% |
| 2022 Q2 | -1.39 Million USD | 38.15% |
| 2022 Q1 | -2.25 Million USD | 3.76% |
| 2022 FY | - USD | 117.56% |
| 2022 Q4 | 6.73 Million USD | 578.42% |
| 2022 Q3 | -1.4 Million USD | -1.02% |
| 2021 FY | - USD | -15.59% |
| 2021 Q2 | -2.27 Million USD | 12.8% |
| 2021 Q1 | -2.61 Million USD | 20.82% |
| 2021 Q3 | -2.34 Million USD | -3.02% |
| 2021 Q4 | -2.34 Million USD | 0.11% |
| 2020 Q1 | -2.27 Million USD | -3.38% |
| 2020 Q3 | -2.09 Million USD | -240.5% |
| 2020 Q4 | -3.29 Million USD | -57.32% |
| 2020 FY | - USD | 5.05% |
| 2020 Q2 | -615.42 Thousand USD | 72.95% |
| 2019 Q2 | -2.94 Million USD | -171.68% |
| 2019 Q3 | -2.3 Million USD | 21.55% |
| 2019 Q4 | -2.2 Million USD | 4.65% |
| 2019 FY | - USD | -49.17% |
| 2019 Q1 | -1.08 Million USD | 15.62% |
| 2018 Q4 | -1.28 Million USD | -20.37% |
| 2018 Q3 | -1.06 Million USD | 13.98% |
| 2018 Q2 | -1.23 Million USD | 45.15% |
| 2018 Q1 | -2.25 Million USD | -6.47% |
| 2018 FY | - USD | -13.28% |
| 2017 FY | - USD | -41.99% |
| 2017 Q4 | -2.12 Million USD | -35.57% |
| 2017 Q3 | -1.56 Million USD | -86.81% |
| 2017 Q2 | -837.95 Thousand USD | -31.54% |
| 2017 Q1 | -637.03 Thousand USD | 68.94% |
| 2016 Q1 | -714.32 Thousand USD | 33.56% |
| 2016 FY | - USD | 53.24% |
| 2016 Q4 | -2.05 Million USD | -145.46% |
| 2016 Q3 | -835.55 Thousand USD | 14.99% |
| 2016 Q2 | -982.85 Thousand USD | -37.59% |
| 2015 FY | - USD | -1067.7% |
| 2015 Q3 | -1.98 Million USD | -31.66% |
| 2015 Q2 | -1.5 Million USD | 0.0% |
| 2015 Q1 | -1.5 Million USD | -785.76% |
| 2015 Q4 | -1.07 Million USD | 45.85% |
| 2014 Q4 | -170.24 Thousand USD | 0.0% |
| 2014 FY | - USD | 19.55% |
| 2013 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 97.531% |
| PainReform Ltd. | -9.56 Million USD | 59.01% |
| Alvotech | -484.86 Million USD | 99.191% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 101.272% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 103.588% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 431.84% |
| Journey Medical Corporation | 1.92 Million USD | 304.183% |
| Dynavax Technologies Corporation | 9.66 Million USD | 140.579% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 97.387% |
| Bright Green Corporation | - USD | Infinity% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 102.408% |
| Embecta Corp. | 245.4 Million USD | 101.598% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -2.561% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -2.561% |
| SCYNEXIS, Inc. | 73.47 Million USD | 105.338% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 6.874% |
| Silver Spike Investment Corp. | 7.34 Million USD | 153.437% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -66.837% |
| Alpha Teknova, Inc. | -25.53 Million USD | 84.642% |
| Safety Shot Inc | -12.18 Million USD | 67.81% |
| Procaps Group, S.A. | 104.02 Million USD | 103.771% |
| Cosmos Health Inc. | -17.06 Million USD | 77.011% |
| Theratechnologies Inc. | -10.31 Million USD | 61.966% |
| Harrow Health, Inc. | 9.72 Million USD | 140.341% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 13.318% |
| Biofrontera Inc. | -18.45 Million USD | 78.744% |
| DURECT Corporation | -24.68 Million USD | 84.11% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 103.992% |
| Cronos Group Inc. | -72.14 Million USD | 94.564% |
| OptiNose, Inc. | -15.55 Million USD | 74.781% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 99.576% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 89.129% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 114.933% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 110.886% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -451.784% |
| Radius Health, Inc. | 38.31 Million USD | 110.238% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -21.999% |
| ProPhase Labs, Inc. | -14.82 Million USD | 73.546% |
| Phibro Animal Health Corporation | 84.6 Million USD | 104.636% |
| Procaps Group S.A. | 104.02 Million USD | 103.771% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 53.311% |
| Viatris Inc. | 3.51 Billion USD | 100.112% |
| Rockwell Medical, Inc. | -4.69 Million USD | 16.439% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -287.584% |
| SIGA Technologies, Inc. | 84.15 Million USD | 104.661% |
| Tilray Brands, Inc. | -72.84 Million USD | 94.615% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 583.049% |
| Shineco, Inc. | -26.55 Million USD | 85.229% |
| PetIQ, Inc. | 81.48 Million USD | 104.814% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -8.423% |
| Incannex Healthcare Limited | -18.5 Million USD | 78.803% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 100.943% |
| Alimera Sciences, Inc. | 7.27 Million USD | 153.908% |
| Assertio Holdings, Inc. | -222.44 Million USD | 98.237% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 1.711% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 76.658% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 80.418% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 97.37% |
| Hempacco Co., Inc. | -12.77 Million USD | 69.292% |
| Talphera, Inc. | -9.84 Million USD | 60.147% |
| Alvotech | -484.86 Million USD | 99.191% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 105.061% |
| Lantheus Holdings, Inc. | 491 Million USD | 100.799% |
| Currenc Group, Inc. | -1.9 Million USD | -106.377% |
| Kamada Ltd. | 21.53 Million USD | 118.215% |
| Indivior PLC | 66 Million USD | 105.943% |
| Evoke Pharma, Inc. | -7.29 Million USD | 46.212% |
| Flora Growth Corp. | -45.87 Million USD | 91.449% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 80.418% |
| Evolus, Inc. | -41.81 Million USD | 90.619% |
| HUTCHMED (China) Limited | 25.52 Million USD | 115.365% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 101.624% |
| Akanda Corp. | -27.73 Million USD | 85.858% |